<DOC>
	<DOCNO>NCT02587650</DOCNO>
	<brief_summary>This phase II multi-center prospective basket trial design test hypothesis target specific kinase fusion metastatic melanoma pre-specified kinase inhibitor result objective tumor shrinkage durable response . The study design 2 stage optimal design sample size N=35 , n1=11 stage I n2=24 stage II . If 1 few response observe stage I , trial stop . If 6 few response observe end stage II , trial stop .</brief_summary>
	<brief_title>Trial TKF Inhibition Unresectable Stage III/IV BRAF/NRAS WT Melanoma</brief_title>
	<detailed_description>This phase II prospective multi-center basket trial design test hypothesis target specific kinase fusion metastatic melanoma kinase inhibitor match activated kinase fusion result tumor response . The study design 2-stage optimal design . Patients screen one eligible fusion protein use various assay develop CLIA-approved laboratory ( target next-generation sequence tumor tissue , fluorescence situ hybridization immunohistochemistry ) separate protocol . If identify , patient offer enrollment protocol treat one five basket . The dose INC280 600 mg PO BID base recommend phase II dose ( RP2D ) Novartis . The dose ceritinib 750 mg PO daily FDA-approved dose ALK-rearranged NSCLC resistant intolerant crizotinib . For regorafenib dose 160 mg PO daily ( first 21 day 28 day cycle ) FDA-approved dose colon cancer GIST . The dose entrectinib 600 mg PO QD RP2D base two Phase 1 study conduct Ignyta .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>General : Inclusion Criteria Ability understand write informed consent document , willingness sign . Age ≥ 18 year ECOG performance status 01 2 pending treatment arm Life expectancy ≥ 12 week Histologically cytologically confirm invasive melanoma . Unresectable Stage III Stage IV melanoma clinical radiographic criterion . Measureable disease RECIST v1.1 . Documentation absence activate targetable BRAF NRAS point mutation . Presence oncogenic kinase fusion involve MET , ROS1 , NTRK1 , NTRK2 , NTRK3 , confirm assay CLIAapproved laboratory . Resolution acute toxic effect ( exclude alopecia ) prior radiotherapy , chemotherapy surgical procedure CTCAE v4.03 grade ≤ 1 . Adequate bone marrow organ function define follow parameter : Adequate bone marrow function : Absolute neutrophil count ≥ 1,500/mm3 Platelets ≥ 75,000/mcL Hemoglobin ≥ 9 g/dL ( transfusion allow ) Adequate hepatic pancreatic function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) . Patients Gilbert 's syndrome may include total bilirubin ≤ 3 x ULN direct bilirubin ≤ 1.5 x ULN AST ( SGOT ) ALT ( SGPT ) ≤ 3 x ULN liver metastases present ; ≤ 5 x ULN liver metastases present Alkaline phosphatase ( ALP ) ≤ 5 x ULN Serum amylase ≤ grade 2 asymptomatic . Patients grade 1 2 serum amylase begin study must confirm sign and/or symptom suggest pancreatitis pancreatic injury ( e.g. , elevated Pamylase , abnormal imaging finding pancreas , etc . ) Serum lipase ≤ ULN Adequate renal function : Creatinine within normal limit creatinine clearance &gt; 40 mL/min ( calculated CockgraftGault ) patient creatinine level ULN Serum potassium , calcium ( correct serum albumin ) , magnesium , phosphorous within normal limit without supplementation Normal coagulation parameter : INR PTT ≤ 1.5 x ULN ( Patients prophylactically treated agent warfarin heparin allow participate , provide prior evidence underlie abnormality coagulation parameter exist . Close monitoring least weekly evaluation perform INR/PTT stable base measurement predose define local standard care . ) General : Exclusion Criteria Uveal melanoma . Current participation another therapeutic clinical trial . Inability swallow intact tablet capsule . Previously identify allergy hypersensitivity component INC280 formulation ( crospovidone , mannitol , microcrystalline cellulose , povidone , sodium lauryl sulfate , magnesium stearate , colloidal silicon dioxide , various coat premix ) , ceritinib formulation , regorafenib Diagnosis concurrent malignancy previous malignancy within 3 year study drug administration ( exception superficial skin cancer , situ cancer deem surgically resect , cure require systemic therapy , indolent malignancy currently require treatment ) . Prior treatment follow antineoplastic therapy within follow time frame : Any prior treatment INC280 , ceritinib , regorafenib , entrectinib cMET HGF , TRK , ROS1 , ALK inhibitor . Thoracic radiotherapy lung field ≤ 4 week prior start INC280 . For anatomic site ( include radiotherapy thoracic vertebra rib ) , radiotherapy ≤ 2 week prior start INC280 . Palliative radiotherapy bone lesion ≤ 2 week prior start INC280 allow . Receipt anticancer investigational agent within 4 week ≤ 5 halflives agent ( whichever longer ) prior first dose INC280 . If previous treatment monoclonal antibody , treatment must discontinue least 4 week first dose INC280 . Major surgery ( e.g. , intrathoracic , intraabdominal intrapelvic ) within 4 week prior ( 2 week resection brain metastasis ) start INC280 . Videoassisted thoracic surgery ( VATS ) mediastinoscopy count major surgery patient enrol study ≥ 1 week procedure . Patients receive treatment medication meet one follow criterion discontinue least 1 week prior start INC280 treatment duration study : Strong moderate inhibitor CYP3A4 Strong inducer CYP3A4 Proton pump inhibitor ( PPI ) Patients unstable increase dos corticosteroid . If patient corticosteroids endocrine deficiency tumorassociated symptom CNS relate , dose must stabilize decrease least 5 day first dose INC280 . Presence history carcinomatous meningitis . Known symptomatic brain metastasis require increase dos steroid manage CNS symptom within 2 week prior study entry . Patients asymptomatic brain metastasis may enrol discretion Sponsor long patient stable require increase dose steroid manage CNS symptoms least 2 week prior study enrollment . Patients require seizure prophylaxis must take nonenzymeinducing anti epileptic drug ( nonEIAED ) . If patient previously EIAEDs discontinue , must discontinue least 1 week prior INC280 administration . If patient require antiepileptic medication , CYP3A4 non EIAED use levetiracetam , valproic acid , gabapentin , topiramate lacosamide . Pregnant nursing woman , woman intend become pregnant study ( pregnancy define state female conception termination gestation , confirm positive serum hCG laboratory test ) . Pregnant woman exclude study study drug either teratogenic unknown teratogenicity . Because unknown potential risk adverse event nurse infant secondary treatment mother , nurse woman exclude unless discontinue breastfeeding study . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 7 day last dose INC280 . Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , post ovulation method ) withdrawal acceptable method contraception . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Combination two follow ( i+ii i+iii ii+iii ) : Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . Barrier method contraception : Condom occlusive cap ( diaphragm cervical/ vault cap ) spermicidal foam/gel/film/cream/vaginal suppository . Women consider postmenopausal childbearing potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g. , ageappropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least 6 week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . Sexually active male unless : A condom use intercourse take drug 7 day last dose entrectinib . Male patient father child 7 day last dose study treatment . Male sterilization take place , appropriate postvasectomy documentation absence sperm ejaculate . Condom use also require vasectomize men order prevent delivery drug via seminal fluid . Any following past 6 month prior screen : Myocardial infarction Severe/unstable angina Clinically significant cardiac arrhythmia Cerebrovascular accident transient ischemic attack Coronary/peripheral artery bypass graft Cardiovascular disorder include : Symptomatic congestive heart failure ( New York Heart Association class III IV ) Personal family history congenital long QT syndrome Corrected QTc &gt; 470 msec use Fridericia correction screen ECG Uncontrolled hypertension ( systolic pressure ≥160 mmHg diastolic pressure ≥100 mmHg repeat measurement ) despite optimal medical management . Initiation adjustment antihypertensive medication allow prior screening . Gastrointestinal disease ( e.g. , Crohn 's disease , ulcerative colitis , short gut syndrome ) malabsorption syndrome would impact drug absorption . Receipt cytotoxic chemotherapy , biologic agent , investigational agent within 4 week prior first dose study drug ( within 6 week nitrosoureas , mitomycin C liposomal doxorubicin ) . Receiving medication meet one follow criterion discontinue least 1 week prior start treatment study drug duration participation : Medication know risk prolong QT interval induce Torsades de Pointes ( please refer http : //www.azcert.org/medicalpros/druglists/drug lists.cfm ) Therapeutic dose warfarin sodium ( coumadin ) coumadin derive anticoagulant . Anticoagulants derive warfarin allow ( e.g. , dabigatran , rivaroxaban , apixaban ) . Enzymeinducing anticonvulsive agent Herbal supplement Any follow past 6 month prior study drug administration : Ventricular arrythmias Supraventricular , nodal , cardiac arrhythmia control medication Cerebrovascular accident transient ischemic attack Coronary/peripheral artery bypass graft Known active infection ( bacterial , fungal , viral include HIV positivity ) . Known history extensive disseminate bilateral interstitial fibrosis interstitial lung disease , include history pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , obliterative bronchiolitis , clinically significant radiation pneumonitis . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration may interfere interpretation study result , judgment Investigator , would make patient inappropriate entry study could compromise protocol objective opinion Investigator and/or Sponsor . Peripheral neuropathy ≥ Grade 2 . Presence nonhealing wound , nonhealing ulcer , bone fracture . History organ allograft ( include corneal transplant ) . Pleural effusion ascites cause respiratory compromise ( dyspnea Grade 2 high ) . Persistent proteinuria ≥ Grade 3 ( &gt; 3.5 g/24 hr , measure urine protein : creatinine ratio random urine sample ) . Patients pheochromocytoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>BRAF Wild-Type ( WT )</keyword>
	<keyword>NRAS Wild-Type ( WT )</keyword>
	<keyword>KRAS Wild-Type ( WT )</keyword>
	<keyword>HRAS Wild-Type ( WT )</keyword>
	<keyword>GNAQ Wild-Type ( WT )</keyword>
	<keyword>GNA11 Wild-Type ( WT )</keyword>
	<keyword>KIT Wild-Type ( WT )</keyword>
</DOC>